(Reuters) – Swiss drugmaker Roche Holding (SIX:) AG is nearing a deal to acquire U.S. biotechnology company Spark Therapeutics Inc, the Wall Street Journal reported on Saturday, citing people familiar with the matter.
The deal for Spark could be announced Monday, if not sooner, at a price tag of nearly $5 billion, but could still fall through, the Journal said, citing the unidentified sources. Spark’s market value was just under $2 billion at Friday’s market close.
The newspaper reported there was at least one other unidentified bidder for Spark as of Friday.
Roche spokeswoman Simone Oeschger said on Saturday the company does not comment on market rumors or speculation. Spark officials could not be reached for comment by Reuters.
Spark is a gene therapy company with a pipeline of potential products targeting blindness, hemophilia and neurodegenerative diseases.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.